Abstract 182P
Background
Combining LEN with anti-PD-1 antibodies (LEN+PD1) has shown promising anti-tumour effect against advanced HCC in KEYNOTE 524 and Study 117. We assessed LEN+PD1 vs LEN monotherapy in Chinese patients (Pts) with advanced HCC.
Methods
This real-world study included Pts with untreated advanced HCC who received lenvatinib (8 mg/d regardless of bodyweight) ± anti-PD-1 antibodies (q3wk) between Nov 2018 and Nov 2019, and had ≥1 efficacy and safety assessment. Endpoints included objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) evaluated using mRECIST and RECIST 1.1 every 2 months from treatment initiation, ALBI score and safety.
Results
The study included 22 patients who received LEN+PD1 and 22 who received LEN. For patients in the LEN+PD1 and LEN groups, median follow-up was 6.6 and 5.3 months, mean age was 54.8 and 53.2 years, 81.8 and 90.9% had BCLC stage C disease, and 72.7 and 68.1% were Child-Pugh A, respectively. ORR and DCR were numerically higher in the LEN+PD1 group vs the LEN group (Table) and median PFS was 12.1 (95% CI: 7.9, 16.2) vs 8.9 months (95% CI: 6.6, 11.2; HR=0.58; 95% CI: 0.17, 1.93), respectively. A similar proportion of patients in both groups decreased one ALBI level from baseline (p=0.9331). The most common AEs in the LEN+PD1 group were hypertension (22.7% [5]), decreased appetite (18.2% [4]) and ALT increase (13.6% [3]) and in the LEN group were ALT increase (31.8% [7]), proteinuria (18.2% [4]) and decreased appetite (18.2% [4]). No unexpected safety signals were observed. Table: 182P
n (%) | RECIST 1.1 | mRECIST | ||||
LEN + PD1 n=22 | LEN n =22 | p | LEN + PD1 n=22 | LEN n =22 | p | |
ORR | 10 (45.5) | 4 (18.2) | 0.052 | 11 (50.0) | 7 (31.8) | 0.220 |
DCR | 20 (90.9) | 17 (77.3) | 0.216 | 20 (90.9) | 17 (77.3) | 0.216 |
Complete response | 1 (4.5) | 0 | 0.204 | 3 (13.6) | 2 (9.1) | 0.526 |
Partial response | 9 (40.9) | 4 (18.2) | 8 (36.4) | 5 (22.7) | ||
Stable disease | 10 (45.5) | 13 (59.1) | 9 (40.9) | 10 (45.5) | ||
Progressive disease | 2 (9.1) | 5 (22.7) | 2 (9.1) | 5 (22.7) |
Conclusions
LEN ± anti-PD-1 antibodies was effective and well tolerated in first-line treatment of patients with advanced HCC. LEN+PD1 showed a trend towards higher ORR, DCR, and longer PFS vs LEN, with no increase in hepatotoxicity. However, further evaluation in randomized, prospective trials is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session